Human CAR-M cells armed with receptors recognizing CD19, CD22, the carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), CD514, and HER2 [220,221], have been developed to target primary and metastatic tumors, mediate phagocytosis, and stably express M1 functions [79]. The gene discussed is CEACAM5; the disease is metastatic neoplasm.